Objective: Angiogenesis occurs within atherosclerotic plaques, and thrombin has been implicated in plaque progression by increasing smooth muscle cell proliferation and upregulating Vascular Endothelial Growth Factor (VEGF) receptor expression. This study investigated the effects of thrombin on key aspects of angiogenesis and expression of pro-and anti-angiogenic regulators: VEGF and Pigment Epithelial Derived Factor. Research Design and Methods: Human umbilical smooth muscle cells (HUASMC) were exposed to vehicle or thrombin at 10 U/ml. To quantify cell proliferation, methyl tetrazolium salt (MTS) solution was added after exposure to thrombin for 24, 48 and 72 hours and the absorbance at 490nm recorded using a plate reader. For Real-time RT-PCR cells were exposed to thrombin for 24hr before analysis of VEGF and PEDF mRNA. A commercial Angiokit was used to construct an in vitro angiogenesis model to measure tubule formation and branching. After 12 days treatment with thrombin 10 U/ml, cells were fixed and the AngioSys 1.0 software was used to analyse tubule morphology. Results: In comparison with controls, thrombin significantly increased HUASMC proliferation (p ¼ 0.002, n ¼ 11) and VEGF mRNA expression by 93% (n ¼ 4, p ¼ 0.024). However in the HUVEC/fibroblast co-cultures it decreased the number of junctions [132 (9) vs 196(18), n ¼ 6, p ¼ 0.017] and tubules [537 (17) vs 589 (26), n ¼ 6, p ¼ 0.049], and tubule length [11393 (1601) vs 12195 (1014), n ¼ 6, p ¼ 0.044], indicating an anti-angiogenic effect. Conclusions: Thrombin stimulates vascular smooth muscle cell proliferation and VEGF expression, but attenuates endothelial cell-mediated growth of vascular tubules and branching of new vascular structures.
Introduction
Thrombin is produced by the enzymatic cleavage of 2 sites on prothrombin, a proenzyme predominantly produced in the liver, and is vitamin K-dependently regulated by the posttranslational modification mechanism. 1 Thrombin has been well established as a pluripotent serine protease in the cascade of the hemostasis and was also evaluated as a therapeutic agent for intraocular bleeding in people with diabetic retinopathy. 2 Recently, the angiogenic property of thrombin has become more significant due to its possible role involving wound healing, atherosclerotic plaques, and tumors. 3 Angiogenesis occurs within atherosclerotic plaques, and thrombin has been implicated in plaque progression by increasing smooth muscle cell proliferation, enhancing the mitogenic activity of endothelial cells (ECs) and upregulating vascular endothelial growth factor (VEGF) receptor expression. 3 However, its effects on the angiogenic cascade including cell proliferation and tubule formation and thrombin's roles in the regulation of angiogenic factors, especially PEDF and VEGF involved in retinopathy, are still controversial.
This study investigated the effects of thrombin on key aspects of angiogenesis, for example, cell proliferation, vascular tubule formation, and expression of pro-and antiangiogenic regulators (VEGF and PEDF).
Materials and Methods

Cell Lines
Bovine retinal capillary endothelial cells (BRCECs) were obtained from freshly slaughtered cattle and cultured according to previously described methods. 4, 5 Human umbilical smooth muscle cells (HUASMCs) in passages 2 or 3 (TCS Cellworks ZHC-3106; TCS CellWorks, Buckingham, United Kingdom) were cultured in smooth muscle cell basal medium (TCS Cellworks) with added smooth muscle cell growth supplement (TCS Cellworks ZHS-8951) and antibiotic supplement (TCS Cellworks ZHR-9939). Plastic materials used for cell culture procedures were precoated with 2% gelatin type B (Sigma, Hertfordshire, United Kingdom).
Cell Proliferation Assay
Six 96-well cell culture plates (Corning, United Kingdom) were precoated with 2% gelatin type B, and left in the flow hood for 2 hours before washing with sterile PBS to remove any excess gelatine. Cells were subcultured and counted. The cells were counted with a hemocytometer, and the desirable cell counts were calculated. The cells were incubated with the control medium or thrombin-a (R&D Systems, Abingdon, Oxfordshire, United Kingdom) at 2 or 10 U/mL (n ¼ 11, respectively). Cell proliferation was measured after 24, 48, and 72 hours incubation by adding methyl tetrazolium salt (MTS) solution 20 mL/well (Promega, Southampton, United Kingdom) and measuring the absorbance at 490 nm. Methyl tetrazolium salt assays were performed twice using both BRCECs and HUASMCs.
Vascular Tubule Formation (Angiokit) Assay
Angiogenesis in vitro was assessed by measuring the ability of HUVEC, when cocultured with matrix-producing fibroblasts, to form capillary-like structures. Human vascular endothelial cells were cocultured with fibroblasts in a 24-well plate to construct an in vitro model of angiogenesis (AngioKit; TCS Cell-Works). Over 12 to 14 days, cellular organization develops from small islands into anastomosing tubular networks. The morphology of the cells in each Angiokit was viewed under the microscope to ensure that the cells had grown well and no contamination was present. A new lid was placed on the kit. Fresh treatments of the control medium or thrombin-a at 10 U/mL were changed on days 1, 4, 7, and 9 (n ¼ 6, respectively). After cell fixing on day 11, vascular structures were visualized by labeling with mouse anti-CD31 and BCIP/NBT substrate according to the manufacturer instructions (TCS CellWorks). Multiple photomicrographs were taken, and angiogenesis was quantified using image analysis software (AngioSys 1.0) to assess tubule number and tubule length and the number of branching points (24). Dedicated image analysis software (AngioSys) was used to analyze the images, and the automatically counted data are expressed as mean and standard deviation (SD). Angiokit assay was repeated twice using same method.
Real-Time Reverse Transcriptase Polymerase Chain Reaction
Human umbilical smooth muscle cells were cultured in 6-well plates (Corns, United Kingdom) to full confluence, starved, and then quiesced in low-serum medium for 24 hours (n ¼ 4). Cells were incubated with the control medium or thrombin-a at 10 U/mL for 24 hours, then lysed. The cells were then lysed, and for each sample, total RNA was extracted with TRIzol Reagent (Sigma, T9424) according to the manufacturer's protocol. The yield of total RNA was measured by spectrophotometry at 260 nm.
The quality and equality of loading of RNA samples was confirmed via agarose gel electrophoresis. A 1 mg aliquot of RNA was used for reverse transcription with the iScript cDNA synthesis kit (Bio-Rad United Kingdom, 170-8890). The following reagents were then added to create a 25-mL polymerase chain reaction (PCR) reaction mix: 2 mL complementary DNA (cDNA), 0.75 mL primers (3 pmol), 9 mL nuclease-free water, and 12.5 mL supermix (Bio-Rad SYBR Green). The PCR mix was denatured at 95 C for 3 minutes, followed by 40 cycles of melting at 95 C for 15 seconds and elongation at 60 C for 45 seconds. Amplification size and reaction specificity were confirmed by melt curve analysis and 1.5% agarose gel electrophoresis. All reactions were performed in duplicate.
Primers used for human cells were b-2 microglobulin (B2M), sense 5 0 -GCT ATC CAG CGT ACT CCA AA-3 0 , antisense 5 0 -GAA AGA CCA GTC CTT GCT GA-3 0 ; PEDF, sense 5 0 -ATC GTC TTT GAG AAG CTG-3 0 , antisense 5 0 -CAA ACT TTG TTA CCC ACT GC-3 0 ; and VEGF, sense 5 0 -CCG CAG ACG TGT AAA TGT TCC T-3 0 , antisense 5 0 -CGG CTT GTC ACA TCT GCA AGT-3 0 .
Quantitative real-time PCR analysis was used to determine the relative levels of gene expression, which used a mathematical model developed for quantifying relative amounts of mRNA to analyze the results based on cycle threshold (Ct) values and the amplification efficiency. 6 Relative PEDF or VEGF gene expression was determined by the use of a mathematical method developed by Pfaffl, 6 normalizing expression to the housekeeping gene, B2M. b-2 microglobulin was confirmed to be unchanged in these experiments (data not shown).
Statistical Analysis
All statistical calculations were undertaken using Smith's Statistical Package Software (SSPS, Version 2.80, California). Results are presented as mean þ standard deviation. Data from the proliferation assay were analyzed using GLM (general linear model) repeated measures to compare the variances from a single treatment in the entire time length. At separate time points, differences were evaluated by analysis of variance (ANOVA). Statistical significance was determined using Student t test for paired comparisons to analysis data from tubule formation assay and real-time RT PCR. P values <.05 were considered statistically significant.
Results
Effects of Thrombin on HUASMCs Proliferation
In comparison with the control, thrombin-a at 2 or 10 U/mL significantly increased HUASMCs growth (P ¼ .002 or P ¼ .001, n ¼ 11), as shown in Figure 1 (overleaf) . However, thrombin did not increase cell growth in the dose-dependent manner.
Effects of Thrombin on BRCECs Proliferation
No significant difference was identified after thrombin-a 10 U/ mL treatment for 24 hours in comparison with the controls (n ¼ 11), as seen in Figure 2 (overleaf).
Effects of Thrombin on Vascular Tubule Formation
In our HUVECs mixed Angiokits, the treatment of thrombin at 10 U/mL decreased tubule formation in vitro, as seen in Figure 3 .
In the tubule formation assay, thrombin-a at 10 U/mL significantly decreased the number of junctions (132 [9] Figure 3 . The images after staining were shown in Figure 4 (overleaf).
Regulation on VEGF and PEDF Expression
On HUASMC, thrombin-a at 10 U/mL significantly increased VEGF expression about 93% (n ¼ 4, P ¼ .024), while no change in PEDF expression at mRNA level was found, as shown in Figure 5 .
Discussion
The mechanism underlying the proangiogenic property of thrombin has been attributed to (1) activation of the quiescent ECs 7 ; (2) time-and dose-dependent upregulation of mRNA for VEGF receptors (KDR, kinase-insert domain receptor and flt-1) 3 ; (3) time-and dose-dependent upregulation of the expression of anb3 integrin, which is a marker of the angiogenic phenotype of ECs 8 ; (4) thrombin receptor-activating peptide (TRAP). This agonist peptide may activate the thrombin receptor and is involved in activating angiogenesis. 7, 9 However, cells seem to respond dissimilarly to thrombin depending on the organ type and species. In macrovessel ECs, it has been reported that, for example, in HUVECs, thrombin stimulated cell proliferation and potentiated the action of various growth factors in the same cells. 7 Whereas, in human or bovine aortic and iliac ECs, thrombin seemed to have an inhibitory effect on proliferation. 10 Thrombin has been clearly identified as a potent enhancer of the proliferation of vascular smooth muscle cells and has also been implicated as a mitogen for smooth muscle cell proliferation contributing to arterial restenosis. 11 The stimulatory effect of thrombin on VSMC had been well established and confirmed in our study. However, human thrombin-a at the higher concentration of 10 U/mL did not show a significant effect on the proliferation of BRCECs. The dissimilarity may derive from species variations or the difference response to micro-or macrovessel ECs.
The Angiokit, used in our study, is a process consisting of multiple steps including cell proliferation and migration, and so on. The previous commonly used tubule formation assays are standard Matrigel assay and growth factors reduced Matrigel assay. The stimulations from growth factors such as VEGF always existed in both culture media, which may lead to false results. Angiokit has much less stimulating factors in comparison with Matrigel and growth factors reduced models. What is more, in the Angiokits assay, tubules more closely resembled capillaries than Matrigel tubules. 12 In our HUVECs mixed Angiokits, decreased tubule formation in vitro was seen in the treatment of thrombin at 10 U/mL. The inhibition effect of thrombin on tubule formation may indicate an antiproliferation role of thrombin at higher concentration.
Thrombin had been also reported to show a stimulating effect on tubule formation in a dose-dependent fashion (0.1-0.3 U/mL) on a laminin-rich reconstituted basement membrane matrix. However, at higher thrombin concentrations (1.0 U/mL), a suppression of tube formation was evident, 13 which was consistent to our finding. Both may indicate that thrombin may act dissimilarly at high concentrations in comparison with low concentrations.
The cascade of angiogenesis had been involved in a variety of multiple signaling pathways. Our previous studies had shown that angiogenic factors may act differently in various concentrations. 14 The dissimilarities on its angiogenic property at various concentrations need cautions in such areas, particularly, as aforementioned, thrombin had once been evaluated in the treatment of proliferative diabetic retinopathy, which is featured by excessive neovascularization. More importantly, thrombin may potentially exaggerate ischemic macrovascular diseases via the inhibition of angiogenesis and lead to insufficient collateral circulation. The reasons responding to such dissimilarity deserve further study.
Thrombin has been reported to increase the expression of VEGF receptors (KDR and flt-1) at the mRNA level in a timeand dose-dependent manner. 3 In this series of experiments, we have identified that thrombin directly increased the expression of VEGF mRNA expression by approximately 1.9-fold in vascular smooth muscle cells. Thrombin exerts no significant effect on the antiangiogenic factor PEDF expression.
Collectively, thrombin acted as a well-established key player in the development of atherosclerosis not only via VSMC accumulation by increasing VSMC proliferation but also via the upregulation of VEGF and its receptors expression. Vascular endothelial growth factor had been reported to enhance atherosclerotic plaque progression and induce plaque destabilization. 15 However, Celletti's report is under debate in a clinical trial of over 800 patients receiving VEGF treatment. There was no evidence of increasing cardiac events even after 18 months follow-up. 16 Ware's research tried to prove the safety of VEGF treatment; however, 18 months follow-up may be not long enough to conclude certain cardiovascular outcome. Further related study would be in need!
Declaration of Conflicting Interest
